Chemotherapy-Induced Diarrhea Market

Market Overview:

The 7 major chemotherapy-induced diarrhea markets reached a value of US$ 84.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 153.1 Million by 2034, exhibiting a growth rate (CAGR) of 5.55% during 2024-2034.

The chemotherapy-induced diarrhea market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Diarrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced diarrhea refers to a distressing side effect that occurs in cancer patients undergoing chemotherapy treatments. It is characterized by irregular and loose bowel movements, often accompanied by abdominal cramping, urgency, and discomfort. This condition can significantly impact a patient's quality of life, leading to dehydration, electrolyte imbalances, malnutrition, and treatment interruptions. The symptoms of the ailment can range from mild to severe, depending on numerous factors, such as the type of chemotherapy drugs used, the dosage, and a patient's overall health. Some individuals suffering from this illness may experience occasional episodes, while others might encounter persistent and debilitating diarrhea. The diagnosis of chemotherapy-induced diarrhea typically involves a thorough assessment by healthcare professionals. Medical history, chemotherapy regimen, and the patient's overall health status are considered. Additionally, laboratory tests, stool cultures, and imaging studies might be utilized to rule out alternative causes and determine the appropriate course of action.

The increasing cases of cancer in which patients undergo potent drug regimens, resulting in disruption of the mucosal membrane of the intestines due to the cytotoxic effects of the treatment, are primarily driving the chemotherapy-induced diarrhea market. In addition to this, the inflating utilization of prophylactic and therapeutic medications, such as loperamide, octreotide, atropine, etc., to alleviate the severity and frequency of the symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of nutritional counseling and diet modifications, which assist in maintaining gut health and restoring digestive balance in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of hydration and electrolyte replacement therapies, given their efficacy in addressing fluid loss and preventing dehydration, is acting as another significant growth-inducing factor. Additionally, the emerging advancements in research and development activities that are focusing on personalized therapeutic strategies based on the genetic and metabolic profiles of patients are also augmenting the market growth. Furthermore, the escalating application of advanced techniques like microbiota-based interventions and targeted therapies that decrease the impact of chemotherapy on gut flora, thereby improving the quality of life, is expected to drive the chemotherapy-induced diarrhea market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced diarrhea market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chemotherapy-induced diarrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced diarrhea market in any manner.

Recent Developments

• In July 2024, Zhiyi Biotech reported favorable findings from a Phase 1 clinical trial in the United States of SK10, an experimental heat-killed Bacteroides fragilis product, for the treatment of chemotherapy-induced diarrhea. This was a randomized, double-blind, placebo-controlled, sequential dose-escalation clinical trial to assess SK10's safety and tolerability in healthy adult participants.

Key Highlights:

• The incidence of all grades of diarrhea after chemotherapy has been reported to be as high as 82%, with up to one-third of patients developing severe diarrhea (grade 3 or 4).
• Chemotherapy-induced diarrhea has been reported to last as long as 10 years post-treatment.
• Chemotherapy-induced diarrhea significantly interferes with anti-cancer treatment, resulting in treatment changes in roughly 60% of patients, dose reductions in 22% of patients, dose delays in 28% of patients, and complete treatment termination in 15% of patients.
• More than 30% of chemotherapy-induced diarrhea patients report that it interferes with their daily activities, which hurts cancer survivors' mental and social health.
• Chemotherapy-induced diarrhea-related dehydration is associated with early fatality rates in approximately 5% of individuals taking anti-cancer treatment.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chemotherapy-induced diarrhea market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chemotherapy-induced diarrhea market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chemotherapy-induced diarrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the chemotherapy-induced diarrhea market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chemotherapy-induced diarrhea market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chemotherapy-induced diarrhea market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chemotherapy-induced diarrhea across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chemotherapy-induced diarrhea by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chemotherapy-induced diarrhea by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chemotherapy-induced diarrhea across the seven major markets?
• What is the size of the chemotherapy-induced diarrhea patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chemotherapy-induced diarrhea?
• What will be the growth rate of patients across the seven major markets?
   

Chemotherapy-Induced Diarrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chemotherapy-induced diarrhea drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced diarrhea market?
• What are the key regulatory events related to the chemotherapy-induced diarrhea market?
• What is the structure of clinical trial landscape by status related to the chemotherapy-induced diarrhea market?
• What is the structure of clinical trial landscape by phase related to the chemotherapy-induced diarrhea market?
• What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced diarrhea market?